In CA, good bioproduction news balances bad

California bioproduction is expanding, showing the potential for manufacturing ramp-ups in recession-hit areas. More CEOs surveyed in the BayBio Report expect to increase manufacturing in-state as opposed to outside the state. Yet more CEOs also plan to cut manufacturing operations in California than in other regions. Article

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.